We have evaluated hMena expression in a series of 286 primary breast cancer (BC) classified in Luminal A (ERα/PR+ HER2-), Luminal B (ERα/PR+ HER2+), Triple Negative (ERα/PR/HER2−) and HER2 subtype (ERα/PR− HER2+), as indicated in Table 1. This evidence concerns the gene PGR and breast carcinoma.